EIGRQ — Eiger Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00- $12.59m
- $28.27m
- $15.77m
Brief: Eiger Biopharmaceuticals William G. Kachioff Appointed As Chief Financial Officer
Brief: Eiger Biopharmaceuticals Reports Q4 And Full Year 2022 Financial Results And Provides Business Update
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Eiger Biopharmaceuticals Inc - Currently Maintains An Account At Silicon Valley Bank Holding Cash Deposits Of Approximately $8.3 Million
Eiger BioPharmaceuticals Inc expected to post a loss of 54 cents a share - Earnings Preview
Brief: Eiger Biopharmaceuticals Inc CFO To Resign Effective Jan 20 2023
Eiger BioPharmaceuticals falls after CEO steps down
Brief: Eiger BioPharmaceuticals Announces Leadership Change
Eiger BioPharmaceuticals plunges after deaths in end-stage trial of HDV therapy
Brief: Eiger Announces Lonafarnib-Based Treatments In Phase 3 D-Livr Trial In Hepatitis Delta Virus Achieve Statistical Significance
Advisory: Alert on Eiger Biopharmaceuticals from law firm withdrawn
U.S. RESEARCH ROUNDUP-Calithera Biosciences, Haynes International, Lumos Pharma
Eiger BioPharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of 52 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Avantor, energy sector, Acumen
U.S. STOCKS ON THE MOVE-Nauticus Robotics, Xos, Monopar
Eiger BioPharmaceuticals to not submit COVID drug application; shares plunge
U.S. STOCKS ON THE MOVE-Relmada, Entera Bio, Eli Lilly
U.S. STOCKS ON THE MOVE-ChannelAdvisor, HyreCar, ADT, miners